Foreign healthcare companies often describe Japan as a difficult digital market. The usual explanation is familiar: conservative institutions, fragmented systems, slow procurement, complex regulation, and a healthcare culture that does not move at startup speed.
That view is not entirely wrong. But it can become dangerously incomplete.
Japan’s healthcare digitization is not only a story about whether hospitals and clinics buy new software. It is also a story about public infrastructure, identity, municipal programs, pharmacies, system vendors, patient workflows, and national platforms that gradually make some kinds of digital operation more normal.
That is why Digital Agency’s latest Public Medical Hub update matters.
On September 7, 2026, Digital Agency updated its Public Medical Hub page, including the list of medical institutions and pharmacies where medical-expense subsidy online qualification confirmation has been introduced. The page describes Public Medical Hub, or PMH, as an information-linkage system connecting local governments, medical institutions, pharmacies, and related actors in areas such as medical-expense subsidies, vaccination, maternal and child health, and other public-service workflows using the My Number card.
The scale is becoming harder to ignore. Digital Agency states that participating or planned municipalities expanded from 183 at the end of fiscal 2024 to 608 as of June 7, 2026, with expected reach toward all 622 municipalities covered in the relevant count. It also states that medical institutions and pharmacies where PMH can be used expanded from about 25,000 in April 2025 to about 69,000 in March 2026.
This does not mean every healthcare workflow in Japan is suddenly digital. It does not mean PMH solves Japan’s healthcare IT fragmentation by itself. It also does not mean foreign vendors can simply plug in and sell.
The more useful signal is different: Japan’s public-medical digital infrastructure is moving from concept to implementation. For foreign companies, that changes the market-entry question.
The old question was: “Is Japan ready for healthcare digitization?”
The better question is now: “Are we ready for the way Japan is digitizing healthcare?”
That distinction matters because Japan’s path is not likely to look like a clean, private-sector SaaS rollout. PMH sits close to public programs, municipal administration, health insurance-style eligibility workflows, medical institutions, pharmacies, My Number card use, and domestic system vendors. A foreign health-tech company that treats this only as a hospital sales problem may miss the actual adoption layer.
The companies most affected are not limited to electronic medical record vendors. The signal is relevant for pharmacy systems, clinic-management platforms, patient intake tools, identity-verification vendors, benefits administrators, insurance-adjacent services, appointment and document tools, maternal and child health platforms, vaccination workflow tools, care-navigation companies, data-integration vendors, and medical SaaS teams that need to interact with public eligibility, patient identity, subsidy, or institutional workflow data.
It also matters for investors. A healthcare product can look promising in a Japan market-entry deck because Japan has an aging population, high medical usage, sophisticated institutions, and demand for productivity. But the route to adoption may depend less on generic demand and more on compatibility with local infrastructure. A product that fits Japan’s emerging administrative workflows may have a different risk profile from a product that requires institutions to create entirely new behavior.
One mistake foreign companies make in Japan is assuming that localization means translation plus compliance review. In healthcare-adjacent markets, localization is deeper. It may mean understanding which actors actually control the workflow, what data can move, what consent or terms apply, how My Number-linked processes are treated, which local vendors already sit inside the institution, and how municipal programs affect patient experience.
PMH is a useful reminder that Japan often digitizes through connected institutional layers rather than through one dramatic market-opening event. A foreign vendor may not be excluded from that process, but it needs to know where it fits. Is it a core system? An integration partner? A clinic-facing add-on? A patient-facing layer? A data-quality tool? A document workflow tool? A product that must work through domestic system vendors? Or a service that is attractive only after public infrastructure normalizes the underlying process?
The operational decision this could change is partner selection.
In many Japan entries, a foreign healthcare company looks first for a distributor, a sales agent, a regulatory advisor, or a hospital reference customer. Those may all be useful. But for PMH-adjacent areas, the more important partner may be a local system vendor, municipal workflow specialist, medical institution IT integrator, pharmacy-system player, or identity / data-linkage expert. The company that introduces you to customers is not always the company that can make your product work inside the Japanese workflow.
It also changes product-market fit assumptions.
If your product depends on patient identity, subsidy eligibility, vaccination records, public medical certificates, pharmacy interactions, or cross-institution administrative data, you need to ask whether the Japanese workflow is becoming easier because PMH-like infrastructure is expanding, or harder because the product must match a specific public implementation path. Either answer can be useful. What is risky is not asking.
Executives should also watch the difference between availability and adoption. A list of medical institutions or pharmacies where a function is available does not automatically tell you how frequently patients use it, how staff experience it, how much training is required, which errors occur, or whether it changes purchasing behavior. Japan often produces reliable infrastructure before it produces visible commercial momentum. Vendors that wait only for obvious demand signals may arrive late. Vendors that move too early without workflow evidence may burn time and budget.
For a foreign operator, the practical diligence questions are straightforward.
First, does the product touch any workflow that Japan is now public-infrastructure digitizing?
Second, which institution owns the workflow: local government, clinic, hospital, pharmacy, insurer, system vendor, patient app, or national platform?
Third, does the company understand the My Number card’s role in the user journey, without assuming that identity infrastructure automatically creates customer acquisition?
Fourth, are there domestic system vendors whose cooperation or compatibility will matter before customers can use the product properly?
Fifth, does the product require behavior change from medical staff, municipal staff, patients, or all three?
Sixth, can the Japan launch plan distinguish between regulatory permission, technical integration, and actual operational adoption?
The overlooked risk is that foreign teams may read Japan’s healthcare digitization too pessimistically or too optimistically.
The pessimistic mistake is assuming Japan is simply slow. That can cause companies to ignore infrastructure changes until domestic competitors and local vendors have already shaped the market. The optimistic mistake is assuming that once a public digital platform expands, commercial entry becomes easy. That can cause companies to underestimate integration, procurement, data governance, workflow fit, and trust requirements.
The better position is more disciplined: Japan is becoming more digitally legible in parts of healthcare, but the route is institutional. Market entry depends on mapping the infrastructure, not just pitching the product.
That is the real significance of the PMH update. It is not a headline about one list being refreshed. It is a sign that public-medical workflow digitization is becoming concrete enough for foreign companies to include in product strategy, partner diligence, and go / wait decisions.
For health-tech and healthcare-adjacent companies, Japan should not be treated as a market that will someday suddenly become digital. Some of the plumbing is already being laid. The question is whether your product is ready for that plumbing, whether your partners understand it, and whether your Japan plan is built around the workflow that is actually emerging.
Japan’s healthcare digital infrastructure is reaching the vendor-readiness stage.
That does not mean every vendor is ready.
Relevant to your business?
Need deeper Japan-specific work on this?
Scope a bespoke Japan Market Entry Research engagement around your objective, constraints and decision deadline.
Japan Market Entry Research · Quote
Need ongoing coverage? Regulatory Risk Assessment · Quote →
Need help interpreting similar signals?
Japan Watchdesk helps overseas teams understand what Japanese-language developments actually mean for commercial decision-making.
Have you encountered something similar?
Share your experience, perspective, or question. Constructive discussion is always welcome.